Debut Plus

₹337.05

▲ +9.59 +2.93%

As of 26 Oct 2026 · delayed

NSE Listed

LT-ASM · ASM 1
What does LT-ASM · ASM 1 mean?
BSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-12
NSE · Long Term Additional Surveillance Measure (ASM 1)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-13

Ind-Swift Laboratories Ltd. (INDSWFTLAB)

Volume: 4,14,766Avg Vol 1W: 4,43,442.6Avg Vol 1M: 4,62,679.652W Range:₹87.15₹424.75
Key Ratios
Checked 7h ago
Market Cap₹2,931 Cr
Current Price₹337.05
Previous Close₹327.46
High / Low (52w)₹424.75 / ₹87.15
Volume4,14,766
Avg Vol (1W)4,43,442.6
Avg Vol (1M)4,62,679.6
Stock P/E45.06
Book Value₹159.06
Dividend Yield0%
ROE357.5%
ROA342.1%
Revenue (TTM)₹696 Cr
Revenue Growth-67.1%
Profit Margin8.62%
Total Debt₹8 Cr
Shares Outstanding9 Cr
Face Value₹10
EPS (TTM)₹7.48
P/B2.12
Debt / Equity0.01
50 DMA₹364.71
200 DMA₹213.38
Day change+2.93%
SurveillanceLT-ASM · ASM 1
Price Chart
₹337.05▲ 224.87% · 1Y
₹413₹881.3Cr
2025-10-27
2026-10-26

20-day avg volume: 4.6L shares

Pros
  • Healthy return on equity of 357.5%.
  • Company is almost debt-free.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹12 Cr₹129 Cr₹138 Cr₹153 Cr₹153 Cr₹151 Cr₹170 Cr₹191 Cr
EBITDA₹1 Cr₹4 Cr₹-12 Cr₹12 Cr₹12 Cr₹23 Cr₹15 Cr₹34 Cr
Net Profit₹0 Cr₹-5 Cr₹222 Cr₹9 Cr₹8 Cr₹10 Cr₹15 Cr₹25 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹643 Cr₹150 Cr₹148 Cr₹150 Cr₹153 Cr₹173 Cr₹696 Cr₹186 Cr
EBITDA₹38 Cr₹-16 Cr₹11 Cr₹13 Cr₹24 Cr₹14 Cr₹63 Cr₹33 Cr
Net Profit₹250 Cr₹218 Cr₹8 Cr₹9 Cr₹11 Cr₹15 Cr₹43 Cr₹24 Cr
EPS35.21—————5.03—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹1,924 Cr₹1,870 Cr₹1,818 Cr₹1,801 Cr₹1,824 Cr₹1,165 Cr₹1,438 Cr₹1,673 Cr
Total Liabilities₹1,336 Cr₹1,229 Cr₹1,215 Cr₹1,200 Cr₹1,142 Cr₹234 Cr₹265 Cr₹289 Cr
Equity₹588 Cr₹641 Cr₹603 Cr₹601 Cr₹682 Cr₹931 Cr₹1,173 Cr₹1,384 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹-64 Cr₹125 Cr₹134 Cr₹150 Cr₹195 Cr₹-163 Cr₹-22 Cr₹-61 Cr
Investing₹-12 Cr₹-9 Cr₹-10 Cr₹5 Cr₹-13 Cr₹-104 Cr₹-113 Cr₹-73 Cr
Financing₹100 Cr₹-133 Cr₹-124 Cr₹-141 Cr₹-186 Cr₹699 Cr₹72 Cr₹142 Cr
Free Cash Flow₹-64 Cr₹125 Cr₹134 Cr₹150 Cr₹195 Cr₹-163 Cr₹-22 Cr₹-61 Cr
Shareholding
Promoter 42.93% Institutions 10.98% Public 46.09%
Efficiency & Working Capital
ROCE4.4%
Interest Coverage45.2
Dividend Payout—
Debtor Days112 d
Inventory Days83 d
Payable Days82 d
Cash Conversion Cycle113 d
Working Capital Days195 d
Shareholding Details

As of 2026-09-30

Promoter42.9%
FII10.8%
DII0.2%
Institutions11%
Public46.1%
Promoter Pledge0%
No. of Shareholders42,667
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodMar 2025Jun 2025Jul 2025Jul 2025Aug 2025Aug 2025Sept 2025Dec 2025Feb 2026Mar 2026Jun 2026Sept 2026
Promoters40.9%40.9%36.8%36.8%39.5%39.5%39.5%39.5%43.1%43%42.9%42.9%
FIIs3.1%4.3%17%17%14.9%14.9%14.8%14.3%13.8%13.9%10.7%10.8%
DIIs0.9%0.9%0.8%0%0.7%0%0.7%0.7%0.2%0%0.2%0.2%
Public55.1%53.9%45.5%46.2%44.9%45.6%45%45.5%43%43.1%46.2%46.1%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders28,11728,70928,90728,90743,98443,98443,78042,12140,40439,22240,88142,667
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Essix Biosciences LimitedShareholding of Promoter and Promoter Group37.8%3.29 Cr
Zeal Global Opportunities FundPublic Shareholding4.6%40,13,561
Nova Global Opportunities Fund Pcc - TouchstonePublic Shareholding3.3%28,88,106
Panchkula Finvest Private LimitedPublic Shareholding2.5%21,55,169
Ashokkumar ChandakPublic Shareholding2.4%21,00,902
Zaki Abbas NasserPublic Shareholding2%17,35,000
Pranav JonejaPublic Shareholding1.4%12,51,401
Ark Global Emerging Companies, LpPublic Shareholding1.4%12,18,000
Sharwan Singh GuleriaPublic Shareholding1.3%11,44,501
Navrattan MunjalShareholding of Promoter and Promoter Group1.2%10,12,479
Rameshkumar Javerchand JainPublic Shareholding1.1%9,90,000
Rishav MehtaShareholding of Promoter and Promoter Group1.1%9,52,357
Chetan ChandakPublic Shareholding1%9,03,019
Nisarg Ajaykumar VakhariaPublic Shareholding1%9,05,000
Manish ChandakPublic Shareholding1%8,78,415
S. R. MehtaShareholding of Promoter and Promoter Group0.6%5,38,980
Himanshu JainShareholding of Promoter and Promoter Group0.6%4,81,256
Gopal MunjalShareholding of Promoter and Promoter Group0.4%3,54,479
V.r. MehtaShareholding of Promoter and Promoter Group0.4%3,41,104
Sunita JainShareholding of Promoter and Promoter Group0.4%3,17,960
Ravi MehtaShareholding of Promoter and Promoter Group0.1%1,07,170
Neeta MunjalShareholding of Promoter and Promoter Group0.1%98,790
Nidhi MunjalShareholding of Promoter and Promoter Group0.1%87,445
Meenakshi MehtaShareholding of Promoter and Promoter Group0.1%71,746
Annie MehtaShareholding of Promoter and Promoter Group0%26,574
Board of Directors
NameDesignationYear
N R MunjalChairman / Executive Director / M D / Promoter2025
Himanshu JainED / Joint MD / Promoter2025
Rishav MehtaExecutive Director2025
Sahil MunjalExecutive Director2025
Neerja ChathleyIndependent Non Executive Women Director2025
Rajinder Kumar GuptaIndependent Non Exe. Director2025
SUBODH GUPTAIndependent Non Exe. Director2025
Prabhat KhuranaIndependent Non Exe. Director2025
Pradeep VermaVP / Company Secretary / Compliance Officer2025
Segments — Product
SegmentRevenueShare
Bulk Drugs & Pharmaceuticals₹0 Cr—
Segments — Geography
RegionRevenueShare
In India₹128 Cr20.9%
Outside India₹484 Cr79.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹101158787
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-10Board Meetings—
forthcoming2026-07-10Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20261702283278
2026000282149
2026170201129
Insider / Designated-Person Trades

3 recent disclosure(s)

PARDEEP VERMADisposal · 6,140
PARDEEP VERMADisposal · 6,140
Essix Biosciences LimitedAcquisition · 51,00,000
Substantial Acquisitions (SAST)

1 disclosure(s)

Pref. Allotment21/07/2025 · 44,85,124
Company Information
Incorporated1995
ChairmanN R Munjal
AuditorRattan Kaur & Associates
🌐 www.indswiftlabs.com ↗

📍 SCO 850 Shivalik Enclave, NAC Manimajra, Chandigarh, Chandigarh, 160101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search